Evidence map›Paper›PMID 33765256›Full record

ArticleInternational journal of hematology2021

High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder.

Hideaki Saito, Hiroaki Miyoshi, Hirohiko Shibayama, Jun Toda, Shinsuke Kusakabe, Michiko Ichii, Jiro Fujita, Kentaro Fukushima, Tetsuo Maeda, Masao Mizuki and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Hideaki SaitoDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Hiroaki MiyoshiDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Hirohiko ShibayamaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan. hiro@bldon.med.osaka-u.ac.jp.ORCID http://orcid.org/0000-0003-4014-2815
Jun TodaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Shinsuke KusakabeDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Michiko IchiiDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Jiro FujitaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Kentaro FukushimaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Tetsuo MaedaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Masao MizukiDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Kenji OritaniDepartment of Hematology, Graduate School of Medical Sciences, International University of Health and Welfare, Chiba, Japan.
Masao SetoDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Takafumi YokotaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Yuzuru KanakuraDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Naoki HosenDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Koichi OhshimaDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
The University of Osaka · JPKurume University · JPInternational University of Health and Welfare · JPSuita Municipal Hospital · JPSumitomo Hospital · JP

Funding

KAKENHI 19K07450
6 · The paper itself

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication of transplantation. In addition to reactivation of Epstein-Barr virus in immunocompromised patients, impaired tumor immunity is suggested to be a risk factor for PTLD. However, it remains unclear whether immune suppressive tumor-infiltrating lymphocytes (TILs) correlate with the occurrence or prognosis of PTLD. We analyzed TILs in 26 patients with PTLD to elucidate the clinicopathological significance of the expression of PD-1 and FoxP3, which are associated with exhausted T-cells and regulatory T-cells (Tregs), respectively. Numbers of PD-1

Indexed as

AdultAgedFemaleForkhead Transcription FactorsHematopoietic Stem Cell TransplantationHumansLymphocytes, Tumor-InfiltratingLymphoma, Large B-Cell, DiffuseLymphoproliferative DisordersMaleMiddle AgedOrgan TransplantationProgrammed Cell Death 1 ReceptorRetrospective StudiesYoung AdultForkhead Transcription FactorsFOXP3 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorFoxP3PD-1PTLDTumor-infiltrating lymphocytes

Identifiers

PMID33765256
OpenAlexW3139479659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.